Disclosure Panels Details Page
Ovarian Cancer Panel - Disclosures as of 07/26/2011
|
Panel Member
(Spouse/Domestic Partner/Dependent) |
Clinical Research Support/Data Safety Monitoring Board | Scientific Advisory Boards, Consultant, or Expert Witness | Promotional Advisory Boards, Consultant, or Speakers Bureau | Employment/ Governing Board, Patent, Equity, or Royalty | Has Attended |
|---|---|---|---|---|---|
| Ronald Alvarez MD | Morphotek Inc. | Eli Lilly and Company Genentech, Inc. GSK Ortho Biotech Products, L.P. |
None | None | ✔ |
| Deborah Armstrong MD | Morphotek Inc. | Boehringer Ingelheim GmbH Genentech, Inc. Genzyme Corporation Oncogenex Ventirx |
None | None | ✔ |
| Barry Boston MD | BEST | Bayer HealthCare Onyx Pharmaceuticals, Inc. Pfizer Inc. sanofi-aventis U.S. |
None | None | - |
| Robert Burger MD, FACOG, FACS | Genentech, Inc. | Eli Lilly and Company GSK Ovagene Pfizer Inc. |
None | None | ✔ |
| Mariana Castells MD, PhD | NA | NA | NA | NA | ✔ |
| Lee-May Chen MD | AstraZeneca Pharmaceuticals LP | None | None | None | ✔ |
| Larry Copeland MD | Eli Lilly and Company Genentech, Inc. Gynecologic Oncology Group |
Genentech, Inc. Precision Therapeutics, Inc. |
None | Gynecologic Oncology Group | - |
| Marta Ann Crispens MD | Morphotek Inc. Spirogen |
None | None | None | ✔ |
| Mary Dwyer MS | None | None | None | None | ✔ |
| Lauren Gallagher | None | None | None | None | ✔ |
| David Gershenson MD | AstraZeneca Pharmaceuticals LP Genentech, Inc. National Cancer Institute |
None | None | Elsevier|Informa|Johnson & Johnson|National Cancer Institute|Pfizer Inc.|Up to Date | ✔ |
| Heidi Gray MD | Abbott Laboratories Prima Biomed |
Prima Biomed | None | None | ✔ |
| Kristina Gregory MSN, RN | None | None | None | None | - |
| Ardeshir Hakam MD | None | None | None | None | - |
| Laura Havrilesky MD | BD TriPath Oncology | BD-TriPath Oncology | None | None | ✔ |
| Miranda Hughes PhD | None | None | None | None | ✔ |
| Carolyn Johnston MD | None | None | None | american cancer society-great lakes division|michigan cancer consortium | ✔ |
| Shashikant Lele MD | None | None | None | None | ✔ |
| Ursula Matulonis MD | AstraZeneca Pharmaceuticals LP Eli Lilly and Company Genentech, Inc. Merck & Co., Inc. |
Eisai Inc. Merck & Co., Inc. |
None | None | ✔ |
| Joan McClure MS | None | None | None | None | ✔ |
| Robert Morgan MD, FACP | NIH-CTEP | None | None | None | ✔ |
| David O'Malley MD | Genentech, Inc. | Johnson & Johnson | None | None | ✔ |
| Richard Penson MD, MRCP | Amgen Inc. CuraGen Corporation Eisai Inc. Eli Lilly and Company Genentech, Inc. ImClone Systems Incorporated PDL BioPharma, Inc. |
None | None | None | ✔ |
| Steven Remmenga MD | None | None | None | None | ✔ |
| Paul Sabbatini MD | None | Genentech, Inc. Johnson & Johnson |
None | None | ✔ |
| Russell Schilder MD | None | Daiichi- Sankyo Co. Morphotek Inc. |
None | None | ✔ |
| Julian Schink | None | None | None | None | ✔ |
| Nelson Teng MD, PhD | NA | NA | NA | NA | ✔ |
| Theresa Werner MD | None | None | None | None | - |